From: Pejman Talebian, MA, MPH, Director Immunization Program
Susan M. Lett, MD, MPH, Medical Director Immunization Program

Date: April 27, 2017
Subject: Availability of Quadracel® (DTaP-IPV) Vaccine and Recommendations for Use

The Massachusetts Department of Public Health (MDPH) is pleased to offer brand choice for combination DTaP-IPV vaccines. In addition to Kinrix® (DTaP-IPV) vaccine manufactured by GlaxoSmithKline, Quadracel® (DTaP-IPV) vaccine manufactured by Sanofi Pasteur is now available for routine ordering.

**Vaccine Schedule**
Quadracel® (DTaP-IPV) vaccine is a combination vaccine approved for the 5th dose of DTaP and the 4th or 5th dose of IPV vaccines in children 4 through 6 years whose previous DTaP doses have been with Sanofi Pasteur's Pentacel® (DTaP-Hib-IPV) and/or Sanofi's Daptacel® (DTaP).

**Inadvertent Administration Out of Approved Age Range**
This vaccine should not be administered before age 4 years or to those 7 years and older.

1) **If Given Before Age 4 Years**
If Quadracel® vaccine is inadvertently administered before age 4 years for an earlier dose of the DTaP and/or IPV series and if minimum interval requirements have been met, the dose may be counted as valid for the DTaP and/or IPV series and does not need to be repeated. Note that if the IPV series must be administered at age ≥4 years regardless of the number of previous doses, and with a minimum interval of 6 months from the previous dose.

2) **If Given At Age 7 Years or Older**
If Quadracel® is inadvertently administered to someone 7 years or older, it can be counted as a valid dose of IPV. For those 7 through 10 years of age, the provider has the option of counting the DTaP dose as a dose of Tdap; or they can give another dose of Tdap routinely at 11-12 years of age (or when next recommended). For those older than 10 years of age, the dose of DTaP counts as the adolescent Tdap dose.
Use of Same Manufacturer Recommended When Feasible
The Advisory Committee on Immunization Practices (ACIP) recommends that, whenever feasible, the same manufacturer’s DTaP vaccines should be used for each dose in the series. However, to avoid missed opportunities, they recommend vaccination should be considered valid and not be deferred when the type of DTaP vaccine previously administered is not available or is not known. Providers wishing to decrease the number of injections may choose to use Quadracel® or Kinrix® in children who received other vaccines for their earlier doses in the series.

Additional Guidance
- The recommendations of the Advisory Committee on Immunization Practices (ACIP) about Quadracel® (MMWR 2015;64, No34:948.) can be found at: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6434a5.htm;
- The 2017 Childhood and Adolescent Immunization Schedule (see footnotes 6 and 12) can be found at: https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf.
- The package insert can be found at: https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM439903.pdf.

Vaccine Ordering
Because Quadracel® is not currently in your inventory, you will need to perform an additional step the first time you order this vaccine. You will need to select “Add Vaccine” at the bottom of the screen after you request doses of the other vaccines you are ordering. From the drop down menu, select “DTaP-IPV” vaccine, and then select “Quadracel”. You should only stock one formulation of DTaP-IPV combination vaccine and it should match your other DTaP combination vaccine (Pediarix® or Pentacel®) that you have in inventory. If you do change formulations of DTaP-IPV combination vaccine, please make sure you use all of your doses of Kinrix®.

Questions
For questions about state supplied vaccine availability and ordering, please contact the Vaccine Management Unit at 617-983-6828. For questions about Quadracel® recommendations and administration, please call the Immunization Program at 617-983-6800 and ask to speak to an immunization epidemiologist.